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1061-154 Serial Assessment of LV Systol ic and Diastolic 
Function During Treatment of Acute Congestive Heart 
Failure 
Craio S. Vinch, Jeffrey C. Hill, Helge Simon, Thee Meyer, Dennis Tighe, Gerard 
Aurigemma, William Gaasch, University of Massachusetts Medical School, Worcester, 
Massachusetts. 
Background; Little is known about how objective indices of left ventricular systolic and 
diastolic function, or neurohumoral levels correlate with clinical improvement after treat- 
ment of acute congestive heart failure (CHF). Indeed, few data are collected during acute 
CHF, when changing hamodynamiss might affect LV function. Methoda: Clinical and 
echo data as well as brain natriuretic peptide (BNP) and norepinephrine (NE) levels were 
collected in 30 pts age 75±10, at presentation, and at 48 hr, after clinical improvement. 
Doppler tissue imaging (DTI) of the lateral mitral annulus was performed: velocity of early 
DTI (E') and the ratio of mitral Doppler early (E) to E' (E/E'), was computed. The diagno- 
sis of CHF was supported by BNP and NE levels, which were significantly elevated com- 
pared to findings in 26 healthy, age-matched controls (control values for BNP=24±5 pg/ 
ml, NE---490-j:72, both p<0.05 compared with CHF pts). Resulta: There was little change 
in EF or most of the variables shown in the Table. SummarylConclualon: During the 
period of observation (4-48 hr), clinical improvement occurred without objective change 
in BNP, NE, or echo indices. These findings are consistent with the notion that either (a) 
BNP, NE, and echo do not change in response to acute treatment of CHF or, more likely, 
(b)changes in these parameters occurred immediately after initial treatment, prior to 
obtaining baseline data. These data are potentially important for the design of studies of 
the short term treatment of CHF. 
EF(%) BPsya DT E E' E/E' BNP NE 
Presentation 45±3 133±4 173±13 96±7 12±1 9±1 1093±250 1187±161 
Follow-up 45±3 122±3" 178±11 92±6 10±1 10±1 1117±246 1027±140 
Data presented as mean + SEE; BP sys and PA pressure in mmHg. E and E' in cm/sec, 
DT in msec. BNP and NE in pg/ml.* p<0.05 vs baseline by t-test 
1061-155 B-Type Natriuratlc Peptide Predicts Sudden Death in 
Patients With Chronic Heart Failure: A Selection Mode 
for ICD Implantation? 
Rudolf M. Berder. Martin Huelsmann, Karin Strecker, Anja Bojic, Richard Pacher, Bdgitte 
Stanek, University of Vienna, Vienna, Austria, Ludwig Boltzman Institute of Experimental 
Endocrinology and of Cardiovascular Research, Vienna. 
Background: Given the high incidence of sudden death in patients with chronic heart fail- 
ure (CHF) and the efficacy of implantible cardioverter defibrillators, an appropdata tool 
for prediction of sudden death is desirable. B-type natriuretic peptide (BNP) has prognos- 
tic significance in CHF and the stimuli for its production also cause electrophysiological 
abnormalities. This study tests BNP levels as predictor of sudden death. 
Methods: BNP levels, in addition to other naurohormonal, clinical and hemodynamic vari- 
ables, were obtained from 452 patients with LVEF < 35%. For prediction of sudden death 
only survivors without HTx or mechanical assist device and patients who died sudden 
were analysed. 
Results: Up to 3 years 293 patients suwivsd without HTx or mechanical assist device, 89 
patients died and 65 patients unterwent HTx. Mode of death was sudden in 44 patients 
(49%), pump failure in 31 patients (35%), 14 patients (16%) died from other causes. 
Univariats dsk factors of sudden death were log BNP (x2=12, P=0.0005), log N-ANP 
(x2=9, P=0.003), LVEF (x2=8, P=0.005), log N-BNP (x2=8, P=0.006), systolic blood 
pressure (x2=6, P=0.01 ), big endothelin (x2=5, P=0.03), NYHA class (x2=4, P=0.04) and 
diastolic blood pressure (x2=4, P<0.05). In the multivariate model log BNP levels were 
the only independent predictor of sudden death (x2=12, P=0.0005). Using a cutpoint of 
log BNP <2.11 (=130 fmol/ml) Kaplan Meier sudden death free survival rates were signif- 
icantly higher in patients below (99%) compared to patients above this cutpoint (81%) 
(P--0.0001). 
Conclusion: BNP levels are a strong independent predictor of sudden death in patients 
with CHF. 
1061-156 B-Type Natriuretic Peptlde in the Emergency Diagnosis 
of Diastolic Dysfunction Heart Failure 
Alan S. Maisel. Patdcia Hlavin, James McCord, Richard M. Nowak, Judd E. Hollander, 
Phillippe Duc, Gabriel Stag, Torbjorn Omland, Ame Westhsim, William T. Abraham, Alan 
B. Storrow, Charles A. McKay, Jr., Alan H. Wu, Peter A. McCullough, BNP Multinational 
Study Investigators, University of California, Veterans Administration Medical Center, San 
Diego, California, University of Missouri, Truman Medical Center, Kansas Ci~ Missouri. 
Background. The emergency department (ED) diagnosis of diastolic dysfunction (DD) 
congestive heart failure (CHF) is difficult based on currently available techniques avail- 
able to ED physicians. We sought to determine the utility of B-type natduretic peptide, as 
a bedside blood test, in the ED diagnosis of DD-CHF. 
Methods. The BNP Multinational Study was a seven-centar, prospective study of 1586 
patients who presented to the ED with acute dyspnea and had BNP measured with a 
point-of-care device upon arrival. A subset of 652 subjects underwent echocardiography 
within 30 days of the ED visit. An ejection fraction (EF) > 45% defined DD in subjects 
who met the gold-standard for CHF as adjudicated by two independent cardiologists, 
blinded to BNP results, who reviewed all clinical data and standardized CHF scores 
(NHANES, Framingham). 
Results. This study subgroup, with mean age of 70.0 years, 56.3% male, contained 489 
(75.0%) found to have CHF. Among those, 184 (37.6%) and 305 (62.4%) had DD-CHF 
and systolic dysfunction (SD) CHF, respectively. The mean BNP levels are displayed in 
the figure. 
JACC March 6, 2002 
Conclusion. A bedside blood test for BNP readily identifies those with DD-CHF com- 
pared to patients with non-cardiac auses of acute dyspnea in the ED. Given the known 
variability in Doppler techniques used to diagnose DD, BNP could become a requisite 
component of the definition of DD-CHF. 
p < 0.0001 for all p~d~Ise compmlsom 
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1061-157 B-Type Natriuratic Peptide Adds to Clinical Judgement 
in the Diagnosis of Heart Failure: A Bayesian Analysis 
From the BNP Multinational Study 
Peter A. McCulloueh. Richard M. Nowak, James McCord, Judd E. Hollander, Gabriel 
Stag, Phillipe Duc, Arne Westheim, Torbjorn Omland, Alan B. Storrow, William T. 
Abraham, Alan H. Wu, Paul Clopton, Leslie Lenert, Alan S. Maisel, BNP Multinational 
Study Investigators, University of Missouri, Truman Medical Center, Kansas City, 
Missouri, University of Califomia, Veterans Administration Medical Center, San Diego, 
Califomia. 
Background, The diagnosis of congestive heart failure (CHF) has been based on clinical 
grounds for decades. We sought to determine the degree to which B-type natriuretic pep- 
tide (BNP) adds to clinical judgement in the diagnosis of CHF. 
Methoda. The BNP Multinational Study was a seven-center, prospective study of 1586 
patients who presented to the ED with acute dyspnea and had BNP measured with a 
point-of-care device upon arrival. Physicians in the ED, blinded to BNP results, gave an 
estimated pre-test probability of CHF based on history, physical exam, and test results 
available in the ED. The gold-standard for CHF was adjudicated by two independent car- 
diologists, also blinded to BNP results, who reviewed all clinical data and standardized 
CHF scores (NHANES, Framingham). 
Reaulta. The final diagnosis was CHF in 804 (50.7%), a history of CHF but dyspnea due 
to noncardiac auses in 138 (8.7%), and not CH F in 644 (40.6%). At a 51% cutoff level of 
pre-test probability of CHF based on clinical judgement, there was a sensitivity of 61.9%, 
specificity of 93.6%, and a likelihood ratio of 9.7. At a cutoff level of 125 pg/ml, BNP had 
a sensitivity of 84.7%, specficity 80.3%, and likelihood ratio of 4.3. In determining the cor- 
rect diagnosis, CHF versus not, clinical judgement and BNP were additive in achieving a 
peak diagnostic accuracy of 93.3% (figure). 
Conclualon. B-type natduretic peptide, as a point-of-care blood test in the ED, adds to 
clinical judgement in acheiving a high-degree of accuracy in the making the diagnosis of 
CHF. 
p < 0.0001 for all p~rMse ¢ompallsons 
Clinical BNP Both 
1061-158 Therapy With the Acorn Cardiac Support Device 
Reduces mRNA Expression of Brain and Atrial 
Natrluratic Peptides in Left Ventricular Myocardium of 
Dogs With Heart Failure 
Shared Restooi. Ramesh C. Gupta, Sudhish Mishra, George Suzuki, Hideaki Modta, 
Hani N. Sabbah, Henry Ford Health System, Detroit, Michigan. 
Background:  Brain (BNP) and atrial (ANP) atduretic paptides increase in heart failure 
(HF) and are associated with poor long-term outcome. The Acorn Cardiac Support 
Device (CSD) is a preformed polyester device that is surgically placed around the cardiac 
ventricles. The CSD was shown to prevent progressive LV dilation, improve LV ejection 
fraction, attenuate stretch response proteins and improve sarcoplasmic reticulum cal- 
cium cycling. In this study we examined the effects of long-term (3 months) therapy with 
the CSD on mRNA gene expression for BNP and ANP in dogs with HF produced by 
intracoronary microembo~izations. 
Methods: Total RNA was extracted from LV myocardium of 6 dogs with HF treated with 
the CSD, 6 dogs with HF that were untreated and 6 normal (NL)dogs. Using specific 
primers, mRNA for BNP and ANP were amplified by reverse transcriptass polymerase 
chain reaction and identified on agorose ethidium bromide gel electrophoresis. Fluorss- 
